Showing 1391-1400 of 2526 results for "".
- Reichert to Distribute Imaging and Dry Eye Treatment Devices in the United Stateshttps://modernod.com/news/reichert-to-distribute-imaging-and-dry-eye-treatment-devices-in-the-united-states/2482016/Reichert Technologies, a business of AMETEK Inc., announced an exclusive partnership with SBM Sistemi of Italy to distribute SBM’s imaging and dry eye assessment and treatment devices in the United States. Financial terms of the deal were not disclosed. </
- Research Unveils Potential Breakthrough in Diabetic Retinopathy Treatmenthttps://modernod.com/news/research-unveils-potential-breakthrough-in-diabetic-retinopathy-treatment/2481962/Researchers from Washington University in St. Louis have discovered a potential new treatment approach to diabetic retinopathy. Diabetic retinopathy’s enigma unfolds with the role of microglia, immune cells resident in the retina. When confronted with high blood glucose levels, th
- Ora and BlindCAN Film Festival Unveil 'The Blind Canvas Project' Using AI to Visualize the Human Experience of Blindnesshttps://modernod.com/news/ora-and-blindcan-film-festival-unveil-the-blind-canvas-project-using-ai-to-visualize-the-human-experience-of-blindness/2481937/Ora and BlindCAN Film Festival announced the launch of 'The Blind Canvas Project,' which aims to use storytelling and generative artificial intelligence (AI) to foster a deeper understanding of the lives and experiences of people living with inherited retinal disease, childhood visua
- Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMDhttps://modernod.com/news/ocular-therapeutix-receives-fda-agreement-under-special-protocol-assessment-spa-for-its-first-pivotal-clinical-trial-of-otx-tki-in-wet-amd/2481928/Ocular Therapeutix announced it has received written agreement regarding the overall design from the FDA under a Special Protocol Assessment (SPA) for the company’s ongoing pivotal phase 3 clinical trial for Axpaxli (axitinib intravitreal implant), for the treatment of wet ag
- EyeSouth Partners Unveils Two Ambulatory Surgery Centers in Orlando and Chicago Areashttps://modernod.com/news/eyesouth-partners-unveils-two-ambulatory-surgery-centers-in-orlando-and-chicago-areas/2481883/EyeSouth Partners has unveiled its two latest surgery centers,
- AEYE Health Makes Its One-Image-Per-Eye Diabetic Eye Exam Faster by Cutting Processing Time to Under 5 Secondshttps://modernod.com/news/aeye-health-makes-its-one-image-per-eye-diabetic-eye-exam-faster-by-cutting-processing-time-to-under-5-seconds/2481874/AEYE Health, a provider of AI-based diabetic retinopathy (DR) screening, announced that it has reduced the processing time for its AEYE-DS diabetic retinopathy screening system to under 5 seconds. This improvement is the result of smarter utilization of computing resources that accelerate th
- University of Toronto Researchers Build Online Glaucoma Simulatorhttps://modernod.com/news/university-of-toronto-researchers-build-online-glaucoma-simulator/2481843/Researchers at the University of Toronto have built an online simulator that is designed to give an improved visual representation of the deterioration caused by glaucoma. The simulator, built by Prof. Willy Wong and PhD candidat
- NovaBay Pharmaceuticals’ Avenova Allograft is Launched in the United Stateshttps://modernod.com/news/novabay-pharmaceuticals-avenova-allograft-is-launched-in-the-united-states/2481830/NovaBay Pharmaceuticals announced the launch of the Avenova Allograft in the United States through its physician-dispensed channel. The company’s prescription optic allograft, which is intended for use as a protective covering during the repair of ocular surfaces, is manufactured using BioS
- Verséa Ophthalmics Will Distribute Celularity’s Biovance and Biovance 3L Ocular Products in the United Stateshttps://modernod.com/news/versea-ophthalmics-will-distribute-celularitys-biovance-and-biovance-3l-ocular-products-in-the-united-states/2481750/Celularity and Verséa Ophthalmics announced that the companies have entered into an exclusive United States commercialization agreement under which Verséa will distribute Celularity’s Biovance and Biovance 3L ocular products. The products are designed to support the
- UnitedHealthcare Launches Virtual Prescription Renewal Option for Contact Lenses and Glasseshttps://modernod.com/news/unitedhealthcare-launches-virtual-prescription-renewal-option-to-help-members-renew-contact-lenses-and-glasses/2481688/UnitedHealthcare has introduced a new virtual prescription renewal option for the millions of members enrolled in its eligible employer-sponsored vision plans. The renewal option aims to make it more convenient and accessible for plan participants to obtain contact lenses and glasses from th